NGM Biopharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.5
- Today's High:
- $1.58
- Open Price:
- $1.55
- 52W Low:
- $1.49
- 52W High:
- $15.616
- Prev. Close:
- $1.51
- Volume:
- 169730
Company Statistics
- Market Cap.:
- $162.12 million
- Book Value:
- 2.323
- Revenue TTM:
- $29.76 million
- Operating Margin TTM:
- -595.96%
- Gross Profit TTM:
- $-125734000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -39.74%
- Return on Equity TTM:
- -70.06%
Company Profile
NGM Biopharmaceuticals Inc had its IPO on 2019-04-04 under the ticker symbol NGM.
The company operates in the Healthcare sector and Biotechnology industry. NGM Biopharmaceuticals Inc has a staff strength of 239 employees.
Stock update
Shares of NGM Biopharmaceuticals Inc opened at $1.55 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.5 - $1.58, and closed at $1.51.
This is a 0% increase from the previous day's closing price.
A total volume of 169,730 shares were traded at the close of the day’s session.
In the last one week, shares of NGM Biopharmaceuticals Inc have slipped by -22.96%.
NGM Biopharmaceuticals Inc's Key Ratios
NGM Biopharmaceuticals Inc has a market cap of $162.12 million, indicating a price to book ratio of 1.4436 and a price to sales ratio of 7.3272.
In the last 12-months NGM Biopharmaceuticals Inc’s revenue was $29.76 million with a gross profit of $-125734000 and an EBITDA of $-174990000. The EBITDA ratio measures NGM Biopharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NGM Biopharmaceuticals Inc’s operating margin was -595.96% while its return on assets stood at -39.74% with a return of equity of -70.06%.
In Q2, NGM Biopharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 82.8%.
NGM Biopharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NGM Biopharmaceuticals Inc’s profitability.
NGM Biopharmaceuticals Inc stock is trading at a EV to sales ratio of 2.0522 and a EV to EBITDA ratio of -0.7936. Its price to sales ratio in the trailing 12-months stood at 7.3272.
NGM Biopharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $220.54 million
- Total Liabilities
- $28.42 million
- Operating Cash Flow
- $24.59 million
- Capital Expenditure
- $104000
- Dividend Payout Ratio
- 0%
NGM Biopharmaceuticals Inc ended 2024 with $220.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $220.54 million while shareholder equity stood at $192.12 million.
NGM Biopharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $28.42 million in other current liabilities, 83000.00 in common stock, $-667541000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $53.27 million and cash and short-term investments were $193.54 million. The company’s total short-term debt was $2,751,000 while long-term debt stood at $0.
NGM Biopharmaceuticals Inc’s total current assets stands at $204.40 million while long-term investments were $0 and short-term investments were $140.27 million. Its net receivables were $736000.00 compared to accounts payable of $5.86 million and inventory worth $1.50 million.
In 2024, NGM Biopharmaceuticals Inc's operating cash flow was $24.59 million while its capital expenditure stood at $104000.
Comparatively, NGM Biopharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.51
- 52-Week High
- $15.616
- 52-Week Low
- $1.49
- Analyst Target Price
- $6
NGM Biopharmaceuticals Inc stock is currently trading at $1.51 per share. It touched a 52-week high of $15.616 and a 52-week low of $15.616. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $2.3 and 200-day moving average was $3.79 The short ratio stood at 14.47 indicating a short percent outstanding of 0%.
Around 2169.6% of the company’s stock are held by insiders while 5975.6% are held by institutions.
Frequently Asked Questions About NGM Biopharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company’s product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.